Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.

ABSTRACT:

Background

Preliminary data suggest that psilocybin-assisted treatment produces substantial and rapid antidepressant effects in patients with major depressive disorder (MDD), but little is known about long-term outcomes.

Aims

This study sought to examine the efficacy and safety of psilocybin through 12 months in participants with moderate to severe MDD who received psilocybin.

Methods

This randomized, waiting-list controlled study enrolled 27 patients aged 21-75 with moderate to severe unipolar depression (GRID-Hamilton Depression Rating Scale (GRID-HAMD) ⩾ 17). Participants were randomized to an immediate or delayed (8 weeks) treatment condition in which they received two doses of psilocybin with supportive psychotherapy. Twenty-four participants completed both psilo

SUBMITTER: Gukasyan N 

PROVIDER: S-EPMC8864328 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature